Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
BOSTON , July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9 , at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021 .
View HTML
Toggle Summary Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON , May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:
View HTML
Toggle Summary Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
– Highlighted distinctive cellular therapy program, market opportunity and value proposition –   Shared optimistic outlook and commitment to deliver value to shareholders –   Encouraged by overwhelming vote of shareholders in favor of the Company proposals on all matters BOSTON , May 19, 2021
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates
– Annual shareholder meeting planned for May 19, 2021 –   Company to host conference call today at 4:30 pm ET   BOSTON , May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the first quarter ended March
View HTML
Toggle Summary Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational Symposium
Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event BOSTON , May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, will present and
View HTML
Toggle Summary Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021
Annual shareholder meeting to be held on May 19, 2021 BOSTON , April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder
View HTML
Toggle Summary Ziopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron’s Virtual Breakthrough Speakers Series
Presentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies BOSTON , April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, was the inaugural
View HTML
Toggle Summary Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
BOSTON and HOUSTON and TAIPEI, Taiwan , April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being
View HTML
Toggle Summary Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers BOSTON and HOUSTON , April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be
View HTML
Toggle Summary Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper ; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance
View HTML